Výsledky vyhledávání - "Federica Ruffini"

Akademický článek

Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential

Autor: Claudia Ceci, Federica Ruffini, Mattia Falconi, Maria Grazia Atzori, Andrea Falzon, Flavia Lozzi, Federico Iacovelli, Stefania D’Atri, Grazia Graziani, Pedro Miguel Lacal

Publikováno v: Biomedicine & Pharmacotherapy, Vol 176, Iss , Pp 116766- (2024)

Activation of neuropilin-1 (NRP-1) by platelet derived growth factor (PDGF)-C sustains melanoma invasiveness. Therefore, in the search of novel agents capable of reducing melanoma spreading, PDGF-C/NRP-1 interaction was investigated as a potential dr

Externí odkaz: https://doaj.org/article/519e23b9a1cf4a4fab62ded4e20b2280

Zobrazit plný text záznamu

Akademický článek

Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors

Autor: Federica Ruffini, Claudia Ceci, Maria Grazia Atzori, Simona Caporali, Lauretta Levati, Laura Bonmassar, Gian Carlo Antonini Cappellini, Stefania D’Atri, Grazia Graziani, Pedro Miguel Lacal

Publikováno v: Pharmacological Research, Vol 192, Iss , Pp 106782- (2023)

Melanoma resistance to BRAF inhibitors (BRAFi) is often accompanied by a switch from a proliferative to an invasive phenotype. Therefore, the identification of signaling molecules involved in the development of metastatic properties by resistant mela

Externí odkaz: https://doaj.org/article/8a4322fd7f85473abdc2bd80fa190bb0

Zobrazit plný text záznamu

Akademický článek

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

Autor: Simona Caporali, Adriana Amaro, Lauretta Levati, Ester Alvino, Pedro Miguel Lacal, Simona Mastroeni, Federica Ruffini, Laura Bonmassar, Gian Carlo Antonini Cappellini, Nadia Felli, Alessandra Carè, Ulrich Pfeffer, Stefania D’Atri

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-24 (2019)

Abstract Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma. Here, we explored the role of miRNAs in melanoma acquired resistance to B

Externí odkaz: https://doaj.org/article/ad44b34751c2441eb4d91f50e0307725

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

Autor: Maria Grazia Atzori, Lucio Tentori, Federica Ruffini, Claudia Ceci, Lucia Lisi, Elena Bonanno, Manuel Scimeca, Eskil Eskilsson, Thomas Daubon, Hrvoje Miletic, Lucia Ricci Vitiani, Roberto Pallini, Pierluigi Navarra, Rolf Bjerkvig, Stefania D’Atri, Pedro Miguel Lacal, Grazia Graziani

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-15 (2017)

Abstract Background Glioblastoma (GBM) is a highly migratory, invasive, and angiogenic brain tumor. Like vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF) promotes GBM angiogenesis. VEGF-A is a ligand for both VEGF recepto

Externí odkaz: https://doaj.org/article/21f609d6b22d4a21bee8c1e043aab86e

Zobrazit plný text záznamu

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

Autor: Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Manuel Scimeca, Rosella Cicconi, Maurizio Mattei, Pedro Miguel Lacal, Grazia Graziani

Publikováno v: Cancers; Volume 14; Issue 22; Pages: 5578

Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family involved in tumor-associated angiogenesis and melanoma invasion of the extra-cellular matrix (ECM) through activation of membrane VEGF receptor 1 (VEGFR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aedefb0e4e89a07f17fba063b67a7a6a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Neuropilin‐1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1

Autor: Mariangela Ungarelli, Veronica Morea, Federica Ruffini, Pedro Miguel Lacal, Angela Orecchia, Gianni Colotti, Patrizio Di Micco, Cristina Maria Failla

Publikováno v: The FEBS journal
(2021): 1–16. doi:10.1111/febs.16119
info:cnr-pdr/source/autori:Colotti G.; Failla C.M.; Lacal P.M.; Ungarelli M.; Ruffini F.; Di Micco P.; Orecchia A.; Morea V./titolo:Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1/doi:10.1111%2Ffebs.16119/rivista:The FEBS journal (Print)/anno:2021/pagina_da:1/pagina_a:16/intervallo_pagine:1–16/volume

Neuropilin-1 (NRP-1) is a semaphorin receptor involved in neuron guidance, and a co-receptor for selected isoforms of the vascular endothelial growth factor (VEGF) family. NRP-1 binding to several VEGF-A isoforms promotes growth factor interaction wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439d945191fca4b8f903527fe4c7a801
https://doi.org/10.1111/febs.16119

Zobrazit plný text záznamu

Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages

Autor: Marta Chiavari, Lucia Lisi, Pedro Miguel Lacal, Gabriella Maria Pia Ciotti, Grazia Graziani, Federica Ruffini, Pierluigi Navarra

Publikováno v: Oncology Reports.

The anti‑vascular endothelial growth factor‑A (VEGF‑A) monoclonal antibody (mAb) bevacizumab is an FDA‑approved monotherapy for the treatment of recurrent glioblastoma (GB), a highly angiogenic and infiltrative tumour. However, bevacizumab do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f96bcc7d33b9781fcaa79d50c9c44f2a
https://doi.org/10.3892/or.2020.7553

Zobrazit plný text záznamu

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib

Autor: Ester Alvino, Federica Ruffini, Gian Carlo Antonini Cappellini, Laura Bonmassar, Lauretta Levati, Stefania D'Atri, Pedro Miguel Lacal, Alessandro Scoppola, Simona Mastroeni, Paolo Marchetti, Simona Caporali

Publikováno v: Oncotarget. 8:113472-113493

The pituitary tumor transforming gene 1 (PTTG1) is implicated in tumor growth, metastasis and drug resistance. Here, we investigated the involvement of PTTG1 in melanoma cell proliferation, invasiveness and response to the BRAF inhibitor (BRAFi) dabr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a9a9a842311f8a1ce9575bbb4e017ee
https://doi.org/10.18632/oncotarget.23052

Zobrazit plný text záznamu

Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib

Autor: Claudia Ceci, Maria Luisa Barbaccia, Pedro Miguel Lacal, Maria Grazia Atzori, Stefania D'Atri, Mauro Trapani, Grazia Graziani, Lucio Tentori, Federica Ruffini

Publikováno v: Journal of Cellular and Molecular Medicine

The vascular endothelial growth factor receptor‐1 (VEGFR‐1) is a tyrosine kinase receptor frequently expressed in melanoma. Its activation by VEGF‐A or placental growth factor (PlGF) promotes tumour cell survival, migration and invasiveness. Mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78649ca9a820f706b95e9d946e535ca5
https://pubmed.ncbi.nlm.nih.gov/31758648

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání